Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G
Istituto Nazionale Neurologico C. Besta, Milano, Italy.
J Neurooncol. 1991 Oct;11(2):165-70. doi: 10.1007/BF02390176.
Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68.5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.
38例恶性胶质瘤患者（27例胶质母细胞瘤和11例间变性星形细胞瘤）术后每月接受多达7个周期的顺铂+依托泊苷治疗。化疗计划在放疗（42 Gy）前进行2个周期，放疗后进行5个周期，采用每日3次分割方案。未观察到严重毒性。本研究的目的是研究顺铂加依托泊苷联合治疗原发性恶性胶质瘤的抗肿瘤效果。本研究中胶质母细胞瘤患者的肿瘤进展时间（TTP）和生存时间（ST）分别为38.5周和68.5周。间变性星形细胞瘤患者的TTP为73周，由于大多数患者仍存活，故未计算ST。术后第18个月，接受（顺铂+依托泊苷）治疗的胶质母细胞瘤患者中有38%仍存活，间变性星形细胞瘤患者中有74%仍存活。本研究表明，顺铂和依托泊苷联合治疗对恶性胶质瘤患者有效。
